Wayshine Biopharm International Ltd. Cayman

FEB 08 2023 WSD0628 has been granted Orphan Drug Designation by FDA

Release time：2023-02-08

WAYSHINE BIOPHARM HOLDING LIMITED ANNOUNCES THE IND APPROVAL BY THE FDA FOR WSD0628 IN COMBINATION WITH RAIDATION THERAPY FOR THE TREATMENT OF RECURRENT BRAIN CANCER
JANUARY 18, 2023Wayshine Biopharm has received IND approval from FDA for its innovative experimental medicine WSD0628, a First-in-Class CNS
Release time：2023-01-19

Wayshine Biopharm Announces WSD0628 Received NCI U19 Funding Support Preclinical and Clinical Development
November 22, 2021--Wayshine Biopharm, a clinical-stage pharmaceutical company, today announced that its First-in-Class CNS pene
Release time：2021-12-01

WAYSHINE BIOPHARM ANNOUNCES WSD0922 RECEIVED FDA ODD R01 FUNDING SUPPORT CLINICAL DEVELOPMENT
October 14, 2021 Wayshine Biopharm, a clinical-stage pharmaceutical company, today announced that its First-in-Class CNS penetrab
Release time：2021-10-18

ORPHAN DRUG DESIGNATION GRANTED BY THE FDA FOR WSD0922
Wayshine Biopharm holding limited Announces ORPHAN DRUG DESIGNATION GRANTED By The FDA For WSD0922 IN GLIOMA (including GLIOBLASTOM
Release time：2019-07-26

April 12,2019 IND approval by FDA
Wayshine Biopharm has received IND approval from FDA about its innovative experimental medicine WSD0922, a First-in-Class CNS penetrable EGF
Release time：2019-04-16

Media Release

About Wayshine

Media